Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1.

Slides:



Advertisements
Similar presentations
Taking Research and Development to the Clinic: Issues for Physicians AAAS/FDLI Colloquium I Diagnostics and Diagnoses Paths to Personalized Medicine Howard.
Advertisements

Warfarin, Insulin and Digoxin are the most Dangerous drugs in the elderly. Do we believe that?
CZ5225 Methods in Computational Biology Lecture 9: Pharmacogenetics and individual variation of drug response CZ5225 Methods in Computational Biology.
FDA Pharmacogenetic Labels A Clinical Perspective David A Flockhart MD, PhD Indiana University School of Medicine Clinical Pharmacology Subcommittee of.
Pavel Tarlykov, PhD General Genetics LTD Astana, Kazakhstan Raleigh, 2014.
Transitions of Care: From Hospital to SNF Steven Tam, MD Assistant Clinical Professor UCI Program in Geriatrics, Internal Medicine.
Pharmacogenetics: From DNA to Drug Treatment Andrew Schork COGS 174 3/14/2012.
Pharmacogenetics and the Management of Breast Cancer: Optimization of Tamoxifen Therapy Mark E. Sobel, M.D., Ph.D. Executive Officer American Society for.
“Empowerment At The Source of Treatment” Psychotropic & Unnecessary Medication Reduction: Rethinking Your Pathway To compliance.
Personalized Medicine: Using a patient’s genomic information (as well as other physiological parameters) to improve the safety and efficacy of pharmacological.
Medication Regimen Review Guidance Training CFR § (c)(1)(2) F428.
Mark W Linder, Ph.D., DABCC, FACB Medical Director, EVP Operations Kristen K. Reynolds Ph.D. Associate Medical Director, VP Laboratory Operations Mark.
A Look at Personalized Medicine Quality Assurance Specialist
Clinical Genotyping and Personalized Medicine Michael D. Kane, PhD (1) Associate Professor of Bioinformatics (2) University Faculty Scholar (3) Chair of.
Prescription Drug Abuse and Misuse in the Elderly Thomas L. Patterson, Ph.D. Support for this work: NIMH Center Grants P30 MH49693 and MH45131, and by.
OPTIMISING MEDICINES USE GRAHAM DAVIES Professor of Clinical Pharmacy & Therapeutics Institute of Pharmaceutical Science King’s College London.
1 PGRx: An Interactive Software System for Integrating Clinical Genotyping with Prescription Drug Safety Assurance. Michael D. Kane, Ph.D. Assistant Professor.
Genetic Testing in Genomic Medicine Gail H. Vance M.D. Professor, Department of Medical & Molecular Genetics Indiana University School of Medicine.
An ABC of Drug-Related Problems RHB Meyboom, M Lindquist, ACG Egberts Drug Safety 2000;22:
Patient Compliance With Medical Advice. Patient compliance (patient adherence) :  The extent to which the patient adheres to medical advice Patient compliance.
Genomics, Bioinformatics & Medicine
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
Pharmacogenomics: advancing personalized medicine.
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Mark Bleackley MEDG 505 March.
Who Are We? Molecular Testing Labs is a cutting-edge molecular and genetics testing laboratory focused on pharmacogenomics. Our primary goal is to provide.
Sales Trainer for PGXL Laboratories
Kristen K. Reynolds, PhD Associate Medical Director, VP Laboratory Operations Copyright 2010 PGXL Laboratories LLC, Louisville KY All materials herein.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 11 Drug Therapy in Geriatric Patients.
Introduction to Precision Medicine
Medication/ Medication Administration
The University of Mississippi Medical Center
Pharmacogenomics. Developing drugs on the basis of individual genetic differences Tailoring therapies to genetically similar subpopulations results in.
Copyright PGXL Laboratories, Louisville KY All materials herein are the exclusive property of PGXL Laboratories PGX Applications in Pain Management.
IF:Pain © PGXL Laboratories. Pain Management - Opioids Problem and Implications 2% to 40% of adults suffer from chronic pain 1 90% of patients.
“Empowerment At The Source of Treatment” Psychotropic & Unnecessary Medication Reduction: Rethinking Your Pathway To compliance.
Polypharmacy and preventing hospital admissions
Foot and Ankle Specialist practicing for over 30 years in the Hudson Valley. Operates six successful practices in the New York Market. His passion has.
IF:Cardiovascular © PGXL Laboratories.
Problems of Polypharmacy
WHAT IS THE EVIDENCE ON EFFECTIVENESS OF ANTIPSYCHOTICS IN PERSONS WITH DEMENTIA? 1.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 8 Individual Variation in Drug Responses.
Pharmacogenetics & Pharmacogenomics Personalized Medicine.
Coverage Indications, Limitations, and/or Medical Necessity This policy limits CYP2C19 (CPT 81225) and CYP2D6 (CPT 81226) genetic testing to defined indications.
Polypharmacy May 2008 CRIT Heidi Auerbach, MD Copyright Boston University Medical Center.
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
Bringing Genomics Home Your DNA: A Blueprint for Better Health Dr. Brad Popovich Chief Scientific Officer Genome British Columbia March 24, 2015 / Vancouver,
Medication Practices for the Elderly in U.S. Nursing Homes Lisa L. Dwyer, MPH Robin E. Remsburg, PhD, APRN, BC Division of Health Care Statistics National.
Drug Therapy in the Elderly
They deserve personalized treatment Your patients are unique.
Pharmacogenetics.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
How Genetic Variants Impact the Safety and Effectiveness of Drugs Pharmacogenetics © PGXL Laboratories.
WHAT IS THE IMPACT OF THE HUMAN GENOME PROJECT FOR DRUG DEVELOPMENT? Arman & Fin.
Origins of Pharmacogenomics. Archibald Garrod In 1902 Garrod characterized the condition of alcaptonuria as one resulting from an absence of the.
Drug efficacy is questioned.. Variation in drug responses.
EVALUATING THE EFFECTIVENESS OF THE AGS UPDATED 2012 BEERS CRITERIA AS AN EDUCATIONAL TOOL IN A FAMILY MEDICINE RESIDENCY TRAINING PROGRAM Eseoghene Abokede.
Pharmacogenetics/Pharmacogenomics. Outline Introduction  Differential drug efficacy  People react differently to drugs Why does drug response vary?
Meet & Greet. Welcome Objectives: 1. Review the core terminology used in pharmacology. 2. Discuss the features of the “perfect” drug. 3. Examine the.
Personalized Medicine
Pharmacogenomics Rita Leone, RN, MSN, CMSRN.
Mahla sattarzadeh Kerman University of Medical Sciences
What’s New in Medication Management: Focus on Older Adults and Caregivers Tuesday, April 30, :00 Noon CDT Mike Varnell, RPh, CSA (214)
Pharmacogenomics Genes and Drugs.
Personalised Medicine ‘into the future’
Introduction to Pharmacogenetics
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Community Pharmacy & Pharmacogenomics: What’s in the DNA Kit
Presentation transcript:

Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1

Current Issues in Medication Management and Pharmacogenomics Brief Biology & Pharmacogenomics Overview Drug Metabolism Clinical Implementation and physician adoption of Pharmacogenomics Main Topics 2

Current Issues in LTC New CMS Five Star Ratings Antipsychotic drugs - 693,000 residents revealed that 32.2% lacked appropriate indications for use 28.5% of the doses received were excessive Adverse Drug Reactions (ADR’s): Over 350,000/yr in nursing homes alone Unnecessary Medications - 27% of residents take 9 or more medications Institute of Medicine, National Academy Press, 2000; Lazarou J et al. JAMA 1998;279(15):1200–1205: Gurwitz JH et al. Am J Med 2000;109(2):87–94 3

Issues Elderly Populations Drug treatments may be unpleasant, painful, and life-threatening Drug Metabolism A patient may need twice the standard dose to be effective A drug works for one patient but not another One patient has side-effects and another doesn’t Drugs Ineffective drugs cost $billions/year 4

Medication-related Problems Falls, dizziness, impaired coordination GI bleeding Headaches, muscle pain, generalized aching/pain Rash, pruritus Seizure activity Spontaneous or unexplained bleeding, bruising Unexplained decline in functional status Urinary retention or incontinence 5

High Cost of Adverse Drug Reactions (ADRs) ADR’s are 4 th leading cause of in death in the US 5 th leading cause of illness 2.2 million hospitalizations per year 28% of hospitalized patients have ADRs Cost of drug related morbidity & mortality = $177 billion 6

Cost of ADR’s in Long Term Care Average hospital cost: $1,939 to $2,595 per ADR Total additional hospital cost: $3 - $4 billion Nursing facilities cost due to ADRs: $7.6 billion Medicare spends $3.5 billion on ADR’s in hospital setting and they account for 2-8% of readmissions 7

Quick Tour of You and Your DNA 46 Chromosomes 3 billion base pairs 100,000 genes capture full human variant Less than 10,000 may be pharmacologically relevant 8

Genes Over 20,000 genes (which encode proteins) 99.9% shared by humans, only 0.1% different 9

SNP’s (“SNIPS”) and DNA Variation SNP’s are a variation in the DNA sequence when a single nucleotide (A, T, C, or G) differs in individuals These DNA variations can affect how humans develop diseases and how they respond to medications 10

Past Approach to Medication Management What if Wilt is a poor metabolizer and Bill is an ultrarapid metabolizer of another pain med? “Adults: take 2 aspirin” Pharmacogenomics is a stronger determinant of efficacy than dosing factors such as age, weight and gender 11

New Definition of Medication Management using Pharmacogenomics “Products and Services that leverage genomics (directly or indirectly) to enable individualized approaches to care, and to choose the right medication at the right dose at the right time” 12

Personalized Medication Management 13

Pharmacogenomics seeks to predict what response an individual will have to a drug Human drug metabolism is largely an inherited trait Pharmacogenomics: “The study of how Genes affect a person’s response to medication” 14

Genes and Drug Metabolism Variations in genes that code for proteins can lead to poor response and ADR’s Cytochrome P450 genes encode enzymes that influence the metabolism of 70-80% of current prescription drugs Common examples are pain meds and antipsychotics, (CYP2D6), Warfarin (CYP2C9 & VKORC1), and Plavix (CYP2C19) 15

Examples of known medication issues Plavix – 19% of Americans are poor metabolizers. The FDA has added warning to Plavix label and recommends genetic testing Warfarin – very narrow therapeutic range; 20% of patients are hospitalized for bleeding within 6 months of starting. Research shows roughly 60% of patients should be prescribed a non- standard dose. Oncology: several drugs have known lethal toxicities and Pharmacogenomic testing is required before administering 16

Interpreting Reports - Genotype and Phenotype Genotypes are the letters of the DNA, or the Genes inside you. You cannot SEE Genotype. Phenotypes are the physical characteristics that you have - you can SEE Phenotype. 17

Drug Response by Phenotype 18

Example: Codeine Metabolism & 2D6 2D6 Phenotype Frequency in population: 19

Codeine Metabolism and Response - Active Drug (Warfarin) takes effect immediately -Prodrug (Codeine) becomes active after metabolism -Poor Metabolizers of Codeine get little or no response 20

Majority of Drugs are Ineffective 21

Individualized Medication Management 22

Pharmacogenomics (PGx) Guided Treatment 23

Variables involved in Personalized Medication Management 24

Physician attitudes towards adoption of PGx 25

26 PGx Test Result Interpretation - Example Reading a Pharmacogenomics Test Report

Current Medications and “Guidance Levels” 27

Current Meds and Guidance Levels (cont) 28

Potentially Impacted Medications and Drug Appendix 29

Physician Report on quality of life improvement: Resident discontinued Risperidone. Zyprexa initiated 2.5mg. Remeron was increased to 15mg. “Behaviors improved and not as many listless days” PGx changes = “red flag” antipsychotic with possible toxic side effects stopped; new antipsychotic (Zyprexa) added; dosage of antidepressant with no warnings increased I n response to PGx test results for this resident, action (in the form of medication changes) was taken in which outcomes improved PGx Case Study Follow-up 30

Benefits of Pharmacogenomics End to Trial and Error - Enables doctors to prescribe the “right dose of the right medicine at the right time” Increase the effectiveness of patient’s medication Reduce or eliminate drug toxicity or treatment failures Decrease adverse drug events (ADR’s) Decrease the total number of drugs taken by an individual 31